Every 8-K that CAMP4 Therapeutics Corporation (CAMP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CAMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAMP filings page.
CAMP4 Therapeutics Corporation (CAMP) outlined its planned Phase 1/2 ASCEND study of CMP-002 for SYNGAP1-related disorder. The randomized, double-blind study will compare intrathecal CMP-002 with a sham pinprick in a 3:1 allocation across three dose cohorts, followed by an open-label extension. The company expects first dosing by the end of 2026 and targets topline data in the first half of 2028.
The planned trial includes participants aged 2 to less than 18 and more than 11 sites across at least nine countries; sites in the United Kingdom, Australia and Argentina have regulatory approval, while European Union sites are under review. CAMP4 described its SHANK3 program for Phelan-McDermid syndrome as preclinical, estimates more than 45,000 patients in the United States, and expects to designate a development candidate in 2027. It is also evaluating programs for two additional early-stage central nervous system haploinsufficient diseases.
CAMP4 Therapeutics reported second quarter 2026 results and clinical progress. Research and collaboration revenue was $1.8 million for the quarter, compared with $1.5 million a year earlier. Research and development expenses were $10.8 million, and general and administrative expenses were $4.3 million, both slightly higher than the prior year period.
Net loss increased to $33.5 million from $12.6 million, driven largely by a $20.9 million non-cash loss from the change in fair value of a derivative tranche liability related to a 2025 private placement. Cash and cash equivalents were $86.4 million as of June 30, 2026, with an additional $50.1 million raised after quarter-end, and the company states this cash is expected to fund planned activities through the end of 2028.
Operationally, CAMP4 obtained regulatory clearance in Australia and Argentina to initiate a first-in-human Phase 1/2 trial of CMP-002 in SYNGAP-1 related disorder, submitted regulatory filings in the EU and UK, completed a second closing of its private placement, and relocated its headquarters to Watertown, Massachusetts.
CAMP4 Therapeutics Corporation completed the second closing of its $100 million private placement, issuing common stock and pre-funded warrants to institutional and accredited investors. This closing raised approximately $50.1 million in gross proceeds before fees.
Investors purchased 10,756,498 shares of common stock at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 each, plus 39,306 shares at $1.65 to certain directors, employees, consultants and company founders. The pre-funded warrants carry a $0.0001 per-share exercise price, are exercisable at any time, may be exercised on a cashless basis, and are subject to a beneficial ownership limitation not exceeding 19.99%. The unregistered offering relied on the Section 4(a)(2) exemption. CAMP4 plans to use net proceeds to advance its lead ASO candidate CMP-002 into a Phase 1/2 trial for SYNGAP1-related disorder, following Australian regulatory clearances, and to support earlier-stage pipeline programs.
On July 27, 2026, CAMP4 Therapeutics Corporation received clearance from Australia’s Therapeutic Goods Administration and a local Human Research Ethics Committee to begin a Phase 1/2 first‑in‑human trial of CMP‑002, its investigational therapy for SYNGAP1‑related disorder, a rare condition with no approved treatments.
This regulatory milestone satisfies conditions under CAMP4’s September 9, 2025 Securities Purchase Agreement, including the CTA Milestone, Price Threshold Waiver and Second Closing Trigger. CAMP4 is now eligible, subject to remaining closing conditions and investor participation, to receive up to approximately $50.1 million in gross proceeds from a second private placement closing in exchange for up to 32,721,172 shares of common stock or pre‑funded warrants, expected on or about August 3, 2026. CMP‑002 is an ASO candidate designed to upregulate SYNGAP1 expression by targeting regulatory RNA, supporting CAMP4’s broader strategy of developing disease‑modifying treatments for genetic disorders.
CAMP4 Therapeutics Corporation reported results from its annual meeting and changes to its equity compensation programs. Stockholders approved an amendment to the 2024 Equity Incentive Plan so that any outstanding pre-funded warrants are included in the year-end share count used in the evergreen formula for annual share increases.
The board also adopted a 2026 Inducement Plan allowing various equity awards covering up to 500,000 shares of common stock, to be used as hiring inducements without separate stockholder approval under Nasdaq Listing Rule 5635(c)(4). Stockholders elected three Class II directors, ratified Ernst & Young LLP as auditor for 2026, and approved the equity plan amendment.
CAMP4 Therapeutics Corporation filed an 8-K to share a corporate update and investor materials highlighting new preclinical data for CMP-002 in SYNGAP1-related disorder. The company presented these findings and an updated slide deck on May 14, 2026.
In a SYNGAP1 haploinsufficient mouse model with chemically induced seizures, a single dose of CMP-002 produced statistically significant improvements in both seizure threshold and seizure severity. These results build on earlier motor and behavioral data, suggesting CMP-002 may address multiple neurological symptoms by restoring SYNGAP1 protein toward healthy levels.
The company describes SYNGAP1-related disorder as a rare central nervous system disease affecting over 10,000 people in the U.S., with high rates of intellectual disability and epilepsy and no approved disease-modifying therapies. CAMP4 expects to advance CMP-002, an antisense oligonucleotide designed to upregulate SYNGAP1, into a global Phase 1/2 clinical trial in the second half of 2026.
CAMP4 Therapeutics reported first quarter 2026 results and highlighted progress in its SYNGAP1 program. The company recorded a net loss of $18.3 million for the quarter, reflecting a non-cash $6.2 million loss from a change in fair value of a derivative tranche liability tied to a prior private placement.
Research and collaboration revenue was $1.3 million, while research and development expenses were $10.2 million and general and administrative expenses were $4.2 million. CAMP4 ended March 31, 2026 with $99.2 million in cash and cash equivalents and expects this to fund planned activities into 2028.
Operationally, the company submitted its first clinical trial regulatory filing for lead candidate CMP-002 in Australia and plans additional global filings in 2026, anticipating a global Phase 1/2 trial in the second half of 2026. CMP-002 received Orphan Designation from the EMA, and CAMP4 initiated a collaboration with CURE SYNGAP1 to support the ProMMiS natural history study.
CAMP4 Therapeutics Corporation announced that its Board of Directors has appointed Michael MacLean as a Class III director, effective April 1, 2026, and expanded the Board from eight to nine members. He will also join the Audit Committee and Compensation Committee.
MacLean brings more than 35 years of financial leadership in biotechnology and life sciences, including serving as Chief Financial Officer of Avidity Biosciences through its IPO and subsequent acquisition by Novartis, and prior senior roles at Akcea Therapeutics, PureTech Health, and Biogen. Under an amended non-employee director compensation policy, he will receive an option to purchase 56,000 shares of CAMP4 common stock, vesting in monthly installments over three years, plus standard cash retainers and the company’s standard director indemnification agreement.
CAMP4 Therapeutics reported full-year 2025 results and highlighted major strategic and financing milestones. Cash and cash equivalents rose to $109.5 million as of December 31, 2025, up from $64.0 million a year earlier, and the company believes this will fund planned activities into 2028.
Research and collaboration revenue increased to $3.5 million, while R&D expenses were $38.2 million and G&A expenses were $17.4 million. Net loss widened to $80.4 million, mainly due to a $29.8 million non-cash loss from a derivative tranche liability tied to a private placement. CAMP4 entered a strategic collaboration with GSK, receiving a $17.5 million upfront payment and potential milestones up to $440 million plus tiered royalties, and completed equity financings totaling $80 million in gross proceeds with potential for an additional $50 million. The company advanced its lead SYNGAP1 program CMP-002 toward a planned global Phase 1/2 trial as early as the second half of 2026 and paused further internal investment in CMP-001 while exploring partnerships.
CAMP4 Therapeutics Corporation reported that it has updated its corporate investor presentation as of January 2026. The company uses this presentation to provide the investment community with updates and summaries of its business. The refreshed materials are available in the Investors section of its website and have also been furnished as Exhibit 99.1 to this report under Regulation FD.
The company notes that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
CAMP4 Therapeutics Corporation entered into an underwriting agreement with Leerink Partners LLC for a public offering of 5,000,000 shares of its common stock at $6.00 per share. All shares are being sold by the company, which estimates net proceeds of approximately $28.0 million after underwriting discounts, commissions, and expenses.
The shares are being issued under an effective Form S-3 shelf registration statement, with a related prospectus supplement filed on December 18, 2025. Closing of the offering is expected on or about December 19, 2025, subject to customary conditions. The company, its executive officers, directors, and certain stockholders agreed to a 60-day lock-up, while sales under the company’s at-the-market program may resume after 30 days from the underwriting agreement date.
CAMP4 Therapeutics Corporation entered into a major Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited to develop antisense oligonucleotide therapeutics for neurodegenerative and kidney disease targets. CAMP4 will use its regulatory RNA mapping and ASO discovery platform to identify and deliver lead ASO series for multiple collaboration targets, after which GSK assumes sole global responsibility for development, regulatory work, manufacturing, and commercialization.
Under the agreement, CAMP4 receives a one-time, non-refundable upfront payment of $17.5 million and is eligible for up to $440 million in development and commercial milestone payments if specified criteria are met, plus tiered royalties from low- to mid-single digits on annual net sales. The agreement includes customary governance, diligence, intellectual property, confidentiality, and indemnification provisions and can be terminated by GSK for convenience or by either party under specified circumstances.
CAMP4 Therapeutics Corporation furnished an update on its business by providing investors with its financial results for the quarter ended September 30, 2025. The company reported these quarterly results through a press release dated November 6, 2025, which is attached as Exhibit 99.1.
The 8-K clarifies that the press release and related information are considered “furnished” rather than “filed” under securities laws, which limits certain legal liabilities and controls how the information may be incorporated into other regulatory documents.
CAMP4 Therapeutics Corporation furnished an update that it has initiated GLP (good laboratory practice) toxicology studies for its program called CMP-SYNGAP-01. These studies are a standard non‑clinical step used to evaluate safety before a potential move into later development stages.
The update was shared through a press release titled “CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01,” which is included as an exhibit to this report. The information is being provided for disclosure purposes and is not being treated as filed under the securities laws unless specifically incorporated by reference elsewhere.
CAMP Therapeutics reported a private placement and related registration rights, board resignations, and management changes. The company entered into a Purchase Agreement providing for sales of securities in one or two closings and agreed to file an initial registration statement within 60 days of the Initial Closing (and, if applicable, a Second Registration Statement within 30 days of a Second Closing) to permit resale of the issued shares and warrant shares. The company committed to use reasonable best efforts to have registration statements become effective within prescribed SEC timelines and to keep them effective under Rule 415 until resale conditions are met. Cash penalties apply for registration failures and customary reciprocal indemnities were granted. Separately, three directors resigned effective September 9, 2025, Douglas Williams, PhD was named Chair, and Daniel Tardiff, PhD was elevated to Chief Scientific Officer effective October 1, 2025. The securities were issued in a private placement relying on Section 4(a)(2).